On March 16, Eastern Time, Cytomx Therap options saw a total of 74657 contracts traded, with calls accounting for 73% and puts making up 26%.
Cytomx Therap has 117447 contracts outstanding, with calls accounting for 94% and puts making up 5%.
The top volume gainer was the 7 dollars Call option expiring on March 20, 2026, with 24537 contracts traded.
On the news front, Based on recent key news:

1. March 16, CytomX Therapeutics announced positive interim Phase 1 data for its experimental cancer drug, varsetatug masetecan, showing robust efficacy in late-line colorectal cancer. This news led to a significant increase in stock price, reaching a new four-year high. The drug's promising results could establish it as a new standard of care for patients who have tried multiple treatments. Source: Reuters

2. March 16, CytomX Therapeutics reported a decrease in operating expenses and a net loss for 2025, but maintained strong cash reserves, supporting its pipeline advancement. The financial update provided confidence in the company's ability to sustain operations and continue drug development. Source: Benzinga

3. March 17, CytomX Therapeutics announced a proposed public offering of common stock and pre-funded warrants, aiming to raise $250 million. This move is expected to bolster the company's financial position and support ongoing clinical trials. Source: ReutersBiotech sector shows strong innovation.
Please note: The chart below does not include options expiring within five days.
<img src="https://assets.lbctrl.com/h5hub/optrank/images/2026-03-17/ST_US_CTMX_en.png" alt="image" original-src="https://assets.lbctrl.com/h5hub/optrank/images/2026-03-17/ST_US_CTMX_en.png"/>

CTMX

On March 16, Eastern Time, Cytomx Therap options saw a total of 74657 contracts traded, with calls accounting for 73% and puts making up 26%.

Trending | CTMX Surges 44% on Monday, Some Call options Surges 94%